The DOI matches its Crossref record.
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.
Abstract
PURPOSE: A meta-analysis was performed on nine randomized clinical trials that compared fluorouracil (5-FU) with 5-FU plus intravenous (IV) leucovorin (LV) for the treatment of advanced colorectal cancer. DESIGN: The analysis was based on the most recently updated individual patient data from all trials. The end points of interest were tumor response and overall survival. RESULTS: Therapy with 5-FU plus LV administered either as weekly or monthly regimens showed a highly significant benefit over single-agent 5-FU in terms of tumor response rate (23% v 11%; response odds ratio (OR), 0.45; P less than 10(-7)). This increase in response did not result in a discernable improvement of overall survival (survival OR, 0.97; P = .57). The large number of patients who did not respond to treatment in both groups, and cross-overs from 5-FU alone to 5-FU plus LV are discussed as plausible explanations for the lack of a survival difference. CONCLUSION: These results confirm the advantage of 5-FU plus leucovorin over 5-FU alone in terms of objective tumor response. They also suggest that in planning future trials, tumor response should not be considered a valid surrogate end point for survival in patients with advanced colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
Glimelius, B., Hoffman, K., Sjödén, P.-O., Jacobsson, G., Sellström, H., Enander, L.-K., Linné, T., & Svensson, C. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010676 · Cited by 797
Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?
Duffy, M. J. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.624 · Cited by 794
Colucci, G., Gebbia, V., Paoletti, G., Giuliani, F., Caruso, M., Gebbia, N., Cartenì, G., Agostara, B., Pezzella, G., Manzione, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.113 · Cited by 779
Lévi, F., Zidani, R., & Misset, J.-L. (1997) · The Lancet · doi:10.1016/s0140-6736(97)03358-8 · Cited by 701
Wolmark, N., Rockette, H., Fisher, B., Wickerham, D. L., Redmond, C., Fisher, E. R., Jones, J., Mamounas, E. P., Ore, L., & Petrelli, N. J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1879 · Cited by 689
Oxaliplatin: A review of preclinical and clinical studies
Raymond, E., Chaney, S. G., Taamma, A., & Cvitkovic, E. (1998) · Annals of Oncology · doi:10.1023/a:1008213732429 · Cited by 643
Folprecht, G., Grothey, A., Alberts, S., Raab, H.-R., & Köhne, C.-H. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi246 · Cited by 632
Nucleoside analogues and nucleobases in cancer treatment
Galmarini, C. M., Mackey, J. R., & Dumontet, C. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00788-x · Cited by 606
Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., Brienza, S., Alafaci, E., Bertheault-Cvitkovic, F., Jasmin, C., et al. (1999) · Annals of Oncology · doi:10.1023/a:1008347829017 · Cited by 606
O'Connell, M. J., Mailliard, J. A., Kahn, M. J., Macdonald, J. S., Haller, D. G., Mayer, R. J., & Wieand, H. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.246 · Cited by 585
Seymour, M. T., Maughan, T. S., Ledermann, J. A., Topham, C., James, R., Gwyther, S. J., Smith, D. B., Shepherd, S., Maraveyas, A., Ferry, D. R., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61087-3 · Cited by 561
Allen-Mersh, T. G., Earlam, S., Fordy, C., Abrams, K., & Houghton, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90750-1 · Cited by 534
Gray, B., Van Hazel, G., Hope, M., Burton, M., Moroz, P., Anderson, J., & Gebski, V. (2001) · Annals of Oncology · doi:10.1023/a:1013569329846 · Cited by 526
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3537 · Cited by 495
Piawah, S., & Venook, A. P. (2019) · Cancer · doi:10.1002/cncr.32163 · Cited by 488
Expanding Criteria for Resectability of Colorectal Liver Metastases
Pawlik, T. M., Schulick, R. D., & Choti, M. A. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0142 · Cited by 449
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer
(1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1356 · Cited by 444
Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
Peters, G. J., Backus, H. H. J., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C. L., Smid, K., Lunec, J., Calvert, A. H., Marsh, S., et al. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00082-0 · Cited by 420
5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development
Grem, J. L. (2000) · Investigational New Drugs · doi:10.1023/a:1006416410198 · Cited by 417
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.104 · Cited by 389
Clinical Pharmacokinetics of Capecitabine
Reigner, B., Blesch, K., & Weidekamm, E. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140020-00002 · Cited by 388
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H.-J., & Ladner, R. D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.51 · Cited by 388
de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., André, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., & Krulik, M. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00370-x · Cited by 386
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): A review
Malet-Martino, M., & Martino, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-4-288 · Cited by 382
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., & Glick, J. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2936 · Cited by 369
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Conti, J. A., Kemeny, N. E., Saltz, L. B., Huang, Y., Tong, W. P., Chou, T. C., Sun, M., Pulliam, S., & Gonzalez, C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.709 · Cited by 344
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
Sobrero, A. F., Aschele, C., & Bertino, J. R. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.368 · Cited by 336
Chinery, R., Brockman, J. A., Peeler, M. O., Shyr, Y., Beauchamp, R. D., & Coffey, R. J. (1997) · Nature Medicine · doi:10.1038/nm1197-1233 · Cited by 334
Köhne, C.-H., van Cutsem, E., Wils, J., Bokemeyer, C., El-Serafi, M., Lutz, M. P., Lorenz, M., Reichardt, P., Rückle-Lanz, H., Frickhofen, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.546 · Cited by 331
Douillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.123 · Cited by 323
Tepper, J. E., O’Connell, M., Niedzwiecki, D., Hollis, D. R., Benson, A. B., Cummings, B., Gunderson, L. L., Macdonald, J. S., Martenson, J. A., & Mayer, R. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.132 · Cited by 321
Van Cutsem, E., Findlay, M., Osterwalder, B., Kocha, W., Dalley, D., Pazdur, R., Cassidy, J., Dirix, L., Twelves, C., Allman, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1337 · Cited by 318
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
Kelly, H., & Goldberg, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.749 · Cited by 316
Basis for effective combination cancer chemotherapy with antimetabolites
Peters, G. J., van der Wilt, C. L., van Moorsel, C. J. A., Kroep, J. R., Bergman, A. M., & Ackland, S. P. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00086-3 · Cited by 301
Bécouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Nguyen, T. D., Paillot, B., Raoul, J. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2739 · Cited by 301
André, T., Bensmaine, M. A., Louvet, C., François, E., Lucas, V., Desseigne, F., Beerblock, K., Bouché, O., Carola, E., Merrouche, Y., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3560 · Cited by 277
Beck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., & Milano, G. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00216-r · Cited by 270
Carmichael, J., Popiela, T., Radstone, D., Falk, S., Borner, M., Oza, A., Skovsgaard, T., Munier, S., & Martin, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.129 · Cited by 268
André, T., Louvet, C., Maindrault-Goebel, F., Couteau, C., Mabro, M., Lotz, J. P., Gilles-Amar, V, Krulik, M., Carola, E., Izrael, V, et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00150-1 · Cited by 267
Pawlik, T. M., Olino, K., Gleisner, A. L., Torbenson, M., Schulick, R., & Choti, M. A. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0149-4 · Cited by 263
André, T., Colin, P., Louvet, C., Gamelin, E., Bouche, O., Achille, E., Colbert, N., Boaziz, C., Piedbois, P., Tubiana-Mathieu, N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.065 · Cited by 262
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
Pitot, H. C., Wender, D. B., O'Connell, M. J., Schroeder, G., Goldberg, R. M., Rubin, J., Mailliard, J. A., Knost, J. A., Ghosh, C., Kirschling, R. J., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2910 · Cited by 258
Folprecht, G., Cunningham, D., Ross, P., Glimelius, B., Di Costanzo, F., Wils, J., Scheithauer, W., Rougier, P., Aranda, E., Hecker, H., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh344 · Cited by 257
(2001) · PubMed · Cited by 194
Michiels, S., Piedbois, P., Burdett, S., Syz, N., Stewart, L., & Pignon, J.-P. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050154 · Cited by 154
Current targeted therapies in the treatment of advanced colorectal cancer: a review
Moriarity, A., O’Sullivan, J., Kennedy, J., Mehigan, B., & McCormick, P. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016646734 · Cited by 87
Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer
Wadler, S., Tenteromano, L., Cazenave, L., Sparano, J. A., Greenwald, E. S., Rozenblit, A., Kaleya, R., & Wiernik, P. H. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685088 · Cited by 43
Metadata
- Venue
- Journal of Clinical Oncology
- Published
- 1992-06
- Volume
- 10
- Issue
- 6
- Pages
- 896-903
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2602544133
- Cited by
- 1,189
- References
- 0
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.